Basic Information
| LncRNA/CircRNA Name | HOXD-AS1 |
| Synonyms | HAGLR, HOXD-AS1, Mdgt |
| Region | GRCh38_2:176164051-176188958 |
| Ensemble | ENSG00000224189 |
| Refseq | NR_033979 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, RNAi, Cell proliferation assay etc. |
| Sample | bladder cancer tissues, cell lines (5637, T24 etc.) |
| Expression Pattern | up-regulated |
| Function Description | We found that the expression level of HOXD-AS1 was significantly increased in bladder cancer tissues and cells. Furthermore, high expression of HOXD-AS1 was significantly related to tumor size, histological grade and TNM stage. In vitro assays confirmed that knockdown of HOXD-AS1 suppressed cell proliferation/migration and increased the rate of apoptotic cell in bladder cancer cells. At last, we used the important element of synthetic biology, tetracycline(tet)-controllable switch, to construct tet-controllable shRNA vectors which can modulate the expression of HOXD-AS1 in a dosage-dependent manner. |
| Pubmed ID | 27328915 |
| Year | 2016 |
| Title | Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. |
External Links
| Links for HOXD-AS1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |